ENVERIC BIOSCIENCES INC (ENVB)       6.93  +0.33 (+5%)

6.93  +0.33 (+5%)

US29405E2081 - Common Stock - Premarket: 7.51 +0.58 (+8.37%)


Fundamental Rating

Taking everything into account, ENVB scores 3 out of 10 in our fundamental rating. ENVB was compared to 264 industry peers in the Pharmaceuticals industry. The financial health of ENVB is medium. Also its profitability is quite bad. ENVB is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating


The profitability ratios for ENVB are negative, so there is not much use analyzing them.
ENVB's Return On Assets of -156.16% is worse than the rest of the industry. The industry average Return On Assets is -37.75%. 95% of the industry peers have a better Return On Assets.

ENVB has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ENVB.
VS Industry

ROA (-156.16%) VS Industry: 5% outperformed.

-838.18
81.41

Valuation

Valuation Rating


With a price book ratio of 0.33, ENVB is valued rather cheaply.
When comparing the price book ratio of ENVB to the average industry price book ratio of 1.90, ENVB is valued rather cheaply. ENVB is also cheaper than 96% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of ENVB to the average industry ratio of 6.38, ENVB is valued rather cheaply.

The Price/Earnings Ratio is negative for ENVB. In the last year negative earnings were reported.
Also next year ENVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.33) VS Industry: 96% outperformed.

117.15
0.17

Enterprise Value/ EBITDA (0.59) VS Industry: 74% outperformed.

886,335.20
0.01

Growth

Growth Rating


ENVB is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 14.71% yearly.
The Revenue has grown by 100.00% in the past year. This is a very strong growth!

ENVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2584.37%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -2584.37% 98.06% 40.72% 25.3% 14.71%
RevenueN/A N/A 100% N/A N/A N/A N/A

Health

Health Rating


ENVB has a Current Ratio of 10.83. This indicates that ENVB is financially healthy and has no problem in meeting its short term obligations.
ENVB is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 3.93.
ENVB has a Quick Ratio of 10.83. This indicates that ENVB is financially healthy and has no problem in meeting its short term obligations.
ENVB is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 3.43.

The Debt to Equity ratio of ENVB is in line with the industry averages.
Based on the Altman-Z score of -7.38, we must say that ENVB is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.01, ENVB is in worse financial state than most of its industry peers. 85% of its industry peers have a better Altman-Z score.
ENVB has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ENVB.
VS Industry

Debt/Equity (0) VS Industry: 55% outperformed.

15.82
0.00

Quick Ratio (10.83) VS Industry: 79% outperformed.

0.08
201.08

Current Ratio (10.83) VS Industry: 79% outperformed.

0.11
201.08

Altman-Z (-7.38) VS Industry: 15% outperformed.

-264.33
625.01

Dividend

Dividend Rating


No dividends for ENVB!.

ENVB Daily chart

ENVERIC BIOSCIENCES INC6.93

NASDAQ:ENVB (8/16/2022, 7:27:21 PM)+0.33 (+5%)

Premarket: 7.51 +0.58 (+8.37%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 05-13 2022-05-13/amc Earnings (Next) 08-23 2022-08-23/bmo
Ins Owners 14.31% Inst Owners 707.86%
Market Cap 8.11M Analysts 80
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.33
EV/EBITDA 0.59
Profitability
ROA -156.16% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y -2584.37% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -2575%
EPS Next Y 98.06% EPS Next 2Y 40.72%
EPS Next 3Y 25.3% EPS Next 5Y 14.71%
Revenue growth 1Y 100% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 10.83 Quick Ratio 10.83
Altman-Z -7.38 F-Score 3
Debt/Equity 0
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA